VWF and systemic sclerosis: Our previous studies proved that it exerts its therapeutic effect on SSc patients by regulating Th17/Treg imbalance, lowering levels of von Willebrand factor (vWF) and aminoterminal propeptide of type III procollagen (PIIINP), and elevating the level of cross-linked carboxyterminal telopeptide of type I collagen (I CTP) [8].